Clinical Trial: TmCD19-IL18 in CD19+ Cancers
Study Status: Completed
Recruit Status: RECRUITING
Condition: Non Hodgkin Lymphoma
Study Type: INTERVENTIONAL
Official Title: Phase I Trial of TmCD19-IL18 CAR T Cells in Patients With Relapsed or Refractory CD19+ Cancers
Brief Summary:
This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, pharmacokinetics, and preliminary efficacy of TmCD19-IL18 CAR T cells in patients with CD19+ cancers.This study will take place in two parts: a Dose-Finding Phase to determine the maximum tolerate dose (MTD), followed by a Dose Expansion Phase.In the Dose-Finding Phase, up to 4 total dose levels will be evaluated using a 3+3 dose escalation design in order to determine the MTD (as defined below).Both…
Read more